Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease

Akel, Hussein; Ismail, Ruba; Csóka, Ildikó

doi:10.1016/j.ejpb.2019.12.014

Cited by 76 publications

(74 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The IN route is composed of three different tracks: the olfactory, the trigeminal and the systemic one, all of which are well described in recent reviews. [36][37][38] Among its pros, IN is a non-invasive procedure, has a rapid kinetics of delivery (minutes), an ease of administration (by the patients themselves or by the caregivers, yielding an increased compliance), and a reduction in the risks of systemic side effects, as the systemic circulation is only partially involved. The main control is the low nasal drug absorption, particularly for hydrophilic drugs, peptides, and proteins.…”

Section: Janus Particlesmentioning

confidence: 99%

“…In this sense, nanotechnology has made a strong contribution since 2007, 39 and, thereafter, polymeric or lipid-based NPs have been developed with the aim of ameliorating the nose-to-brain delivery of a variety of drugs. 40 Both these classes of NPs present advantages and disadvantages 38 and, although an updated revision of the recent literature has been done by Akel and colleagues., 37 still more comparative studies are needed.…”

Section: Janus Particlesmentioning

confidence: 99%

See 1 more Smart Citation

<p>Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)</p>

Binda¹,

Murano²,

Rivolta³

2020

IJN

View full text Add to dashboard Cite

The field of nanomedicine is constantly expanding. Since the first work dated in 1999, almost 28 thousand articles have been published, and more and more are published every year: just think that only in the last five years 20,855 have come out (source PUBMED) including original research and reviews. The goal of this review is to present the current knowledge about nanomedicine in Alzheimer's disease, a widespread neurodegenerative disorder in the over 60 population that deeply affects memory and cognition. Thus, after a brief introduction on the pathology and on the state-of-the-art research for NPs passing the BBB, special attention is placed to new targets that can enter the interest of nanoparticle designers and to new promising therapies. The authors performed a literature review limited to the last three years (2017-2020) of available studies with the intention to present only novel formulations or approaches where at least in vitro studies have been performed. This choice was made because, while limiting the sector to nanotechnology applied to Alzheimer, an organic census of all the relevant news is difficult to obtain.

show abstract

Section: Janus Particlesmentioning

confidence: 99%

Section: Janus Particlesmentioning

confidence: 99%

<p>Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)</p>

Binda¹,

Murano²,

Rivolta³

2020

IJN

View full text Add to dashboard Cite

show abstract

“…The absorption of drugs from the nasal cavity and their transport to the brain or into the systemic circulation are influenced by mucociliary clearance. This is a physiological defense mechanism of the respiratory system which eliminates external substances by covering them with a layer of mucus, reducing the residence time of drugs administered intranasally [ 62 ]. However, the mucoadhesive property of chitosan is also responsible for the decrease of mucociliary clearance, because it adheres to the nasal mucosa and inhibits mucociliary development and differentiation by increasing the factor TGF-b1 [ 55 , 56 ].…”

Section: Properties Of Chitosan and Its Derivativesmentioning

confidence: 99%

“…Many of these disadvantages are overcome by formulating chitosan-based drug delivery systems, due to their properties, previously presented in this paper: Biocompatibility, biodegradability, non-toxicity, mucoadhesion, and permeability enhancer role [ 108 ]. There are also issues related to the safety of formulations based on chitosan and its derivatives that need to be investigated, such as the toxicity of the pharmaceutical forms, drug release, the stability of the systems [ 31 ], and the safety of the long-term administration of nasal drugs and vaccine delivery systems [ 62 ].…”

Section: The Nasal Routementioning

confidence: 99%

See 1 more Smart Citation

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan

Popescu

Ghica

Dinu-Pîrvu

et al. 2020

IJMS

View full text Add to dashboard Cite

In an attempt to develop drug delivery systems that bypass the blood–brain barrier (BBB) and prevent liver and intestinal degradation, it was concluded that nasal medication meets these criteria and can be used for drugs that have these drawbacks. The aim of this review is to present the influence of the properties of chitosan and its derivatives (mucoadhesion, permeability enhancement, surface tension, and zeta potential) on the development of suitable nasal drug delivery systems and on the nasal bioavailability of various active pharmaceutical ingredients. Interactions between chitosan and proteins, lipids, antigens, and other molecules lead to complexes that have their own applications or to changing characteristics of the substances involved in the bond (conformational changes, increased stability or solubility, etc.). Chitosan and its derivatives have their own actions (antibacterial, antifungal, immunostimulant, antioxidant, etc.) and can be used as such or in combination with other molecules from the same class to achieve a synergistic effect. The applicability of the properties is set out in the second part of the paper, where nasal formulations based on chitosan are described (vaccines, hydrogels, nanoparticles, nanostructured lipid carriers (NLC), powders, emulsions, etc.).

show abstract

Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen‐Based Nanomedicines

Wu,

Wang,

Deng

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Plasmalogens (vinyl‐ether phospholipids) are an emergent class of lipid drugs against various diseases involving neuro‐inflammation, oxidative stress, mitochondrial dysfunction, and altered lipid metabolism. They can activate neurotrophic and neuroprotective signaling pathways but low bioavailabilities limit their efficiency in curing neurodegeneration. Here we created liquid crystalline lipid nanoparticles (LNPs) for protection and non‐invasive intranasal delivery of purified scallop‐derived plasmalogens. Our in vivo results with a transgenic mouse Parkinson's disease (PD) model (characterized by motor impairments and α‐synuclein deposition) demonstrated the crucial importance of LNP composition, which determines the self‐assembled nanostructure type. Vesicle and hexosome nanostructures (characterized by SAXS) displayed different efficacy of the nanomedicine‐mediated recovery of motor function, lipid balance, and transcriptional regulation (e.g., reduced neuro‐inflammation and PD pathogenic gene expression). Intranasal vesicular and hexosomal plasmalogen‐based LNP treatment led to improvement of the behavioral PD symptoms and downregulation of the Il6, Il33, and Tnfa genes. Moreover, RNA‐sequencing and lipidomic analyses established a dramatic effect of hexosomal nanomedicines on PD amelioration, lipid metabolism, and the type and number of responsive transcripts that may be implicated in neuroregeneration.This article is protected by copyright. All rights reserved

show abstract

Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease

Cited by 76 publications

References 180 publications

<p>Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)</p>

<p>Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)</p>

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan

Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen‐Based Nanomedicines

Contact Info

Product

Resources

About